Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2023 Sep;34(9):806-812.
doi: 10.1016/j.annonc.2023.06.006. Epub 2023 Jul 4.

Long-term outcomes to neoadjuvant pembrolizumab based on pathological response for patients with resectable stage III/IV cutaneous melanoma

C E Sharon  1 , G N Tortorello  1 , K L Ma  1 , A C Huang  2 , X Xu  3 , L R Giles  4 , S McGettigan  4 , K Kreider  4 , L M Schuchter  4 , A J Mathew  5 , R K Amaravadi  4 , P A Gimotty  6 , J T Miura  7 , G C Karakousis  7 , T C Mitchell  8
Affiliations
Clinical Trial

Long-term outcomes to neoadjuvant pembrolizumab based on pathological response for patients with resectable stage III/IV cutaneous melanoma

C E Sharon et al. Ann Oncol. 2023 Sep.

Erratum in

Abstract

Background: While neoadjuvant immunotherapy for melanoma has shown promising results, the data have been limited by a relatively short follow-up time, with most studies reporting 2-year outcomes. The goal of this study was to determine long-term outcomes for stage III/IV melanoma patients treated with neoadjuvant and adjuvant programmed cell death receptor 1 (PD-1) inhibition.

Patients and methods: This is a follow-up study of a previously published phase Ib clinical trial of 30 patients with resectable stage III/IV cutaneous melanoma who received one dose of 200 mg IV neoadjuvant pembrolizumab 3 weeks before surgical resection, followed by 1 year of adjuvant pembrolizumab. The primary outcomes were 5-year overall survival (OS), 5-year recurrence-free survival (RFS), and recurrence patterns.

Results: We report updated results at 5 years of follow-up with a median follow-up of 61.9 months. No deaths occurred in patients with a major pathological response (MPR, <10% viable tumor) or complete pathological response (pCR, no viable tumor) (n = 8), compared to a 5-year OS of 72.8% for the remainder of the cohort (P = 0.12). Two of eight patients with a pCR or MPR had a recurrence. Of the patients with >10% viable tumor remaining, 8 of 22 patients (36%) had a recurrence. Additionally, the median time to recurrence was 3.9 years for patients with ≤10% viable tumor and 0.6 years for patients with >10% viable tumor (P = 0.044).

Conclusions: The 5-year results from this trial represent the longest follow-up of a single-agent neoadjuvant PD-1 trial to date. Response to neoadjuvant therapy continues to be an important prognosticator with regard to OS and RFS. Additionally, recurrences in patients with pCR occur later and are salvageable, with a 5-year OS of 100%. These results demonstrate the long-term efficacy of single-agent neoadjuvant/adjuvant PD-1 blockade in patients with a pCR and the importance of long-term follow-up for these patients.

Trial registration: Clinicaltrials.gov, NCT02434354.

Keywords: follow-up studies; immunotherapy; melanoma; neoadjuvant therapy; programmed cell death 1 receptor.

PubMed Disclaimer

Conflict of interest statement

Disclosure GCK serves on an advisory board of Merck. All remaining authors have declared no conflicts of interest.

Figures

Figure 1.
Figure 1.
Overall survival. Five-year overall survival of patients with resectable stage III/IV cutaneous melanoma who received one dose of neoadjuvant pembrolizumab (200 mg) followed by surgical resection, and an additional year of adjuvant pembrolizumab stratified by (A) pathological response and (B) patterns of posttreatment tumor-infiltrating lymphocytes.
Figure 2.
Figure 2.. Recurrence-free survival.
Five-year recurrence-free survival of patients with resectable stage III/IV cutaneous melanoma who received one dose of neo-adjuvant pembrolizumab (200 mg) followed by surgical resection, and an additional year of adjuvant pembrolizumab stratified by (A) pathological response and (B) patterns of post-treatment tumor-infiltrating lymphocytes.
See this image and copyright information in PMC

References

    1. Blank CU, Rozeman EA, Fanchi LF, et al. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat Med 2018;24(11):1655–1661. - PubMed
    1. Amaria RN, Prieto PA, Tetzlaff MT, et al. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol 2018;19(2):181–193. - PubMed
    1. Huang AC, Orlowski RJ, Xu X, et al. A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. Nat Med 2019;25(3):454–461. - PMC - PubMed
    1. Najjar YG, McCurry D, Lin H, et al. Neoadjuvant pembrolizumab and high-dose IFNa-2b in resectable regionally advanced melanoma. Clin Cancer Res 2021;27(15):4195–4204. - PMC - PubMed
    1. Sharon CE, Karakousis GC. Educational review: neoadjuvant approaches to melanoma. Ann Surg Oncol 2022;29(13):8492–8500. - PubMed

Publication types

Substances

Associated data